Eli Lilly stock jumps 10% on annual guidance hike, strong Q2 top and bottom line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
August 9, 2024 5:56 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $1,150.00 (from $1,000.00) while maintaining a Buy rating.
The analyst comments "LLY shares traded with strength today (+9.5%; DRG index: +4%) following the continued outperformance from Lillys incretin portfolio, including Mounjaro (Type 2 diabetes) and Zepbound (obesity). Importantly, given managements... More
Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance
August 8, 2024 6:47 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $3.92, $1.17 better than the analyst estimate of $2.75. Revenue for the quarter came in at $11.3 billion versus the consensus estimate of $10 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2024 EPS of $16.10-$16.60, versus the... More
